Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer — Stella

Home/Anti-PD-1 Antibody/

View on ClinicalTrials.gov

Recruiting

Back to Anti-PD-1 Antibody trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

China

West China Hospital of Sichuan University, Chengdu, Sichuan

Key details

Phase

Early testing / Safety & dosing

Sponsor

West China Hospital

Collaborators

First Affiliated Hospital of Chongqing Medical University, Yunnan Cancer Hospital

Enrollment target

~20 participants

Started

August 2020

Primary completion

December 2024

This trial's estimated completion date has passed — the record may not be fully up to date.

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

Age range

18 Years and older

Last updated August 2024